Amendment to Additional Investment Right Agreement between Generex Biotechnology Corporation and Omicron Master Trust
Contract Categories:
Business Finance
›
Modification Agreements
Summary
Generex Biotechnology Corporation and Omicron Master Trust have agreed to amend the terms of an additional investment right originally issued on June 17, 2005. This amendment allows Omicron to exercise its right to purchase a $500,000 debenture earlier than previously permitted, provided Omicron delivers a Notice of Exercise by the close of business on October 27, 2005. The agreement confirms Generex will honor this early exercise.
EX-4.6 7 v027992_ex4-6.htm
Exhibit 4.6
October 27, 2005
Omicron Master Trust
650 Fifth Avenue
24th Floor
New York, New York
USA 10019
Attention: Brian Daly
Dear Sirs:
| Re: | Generex Biotechnology Corporation - Amendment to Jun 17 05 Additional Investment Right |
We make reference to the additional investment right issued by Generex Biotechnology Corporation (the “Company”) to Omicron Master Trust (“Omicron”) on June 17, 2005 pursuant to which the Company, inter alia, granted to Omicron the right to purchase a $500,000 principal amount debenture (the “AIR”).
The Initial Exercise Date (as that term is defined in the AIR) of the AIR is expressed therein as the 181st day after the date thereof. The Company hereby confirms that, in consideration of the exercise of the AIR by Omicron and the delivery to the Company of a Notice of Exercise in respect thereof on or before the close of business on October 27, 2005, the Company has agreed to abridge the Initial Exercise Date and to honor the aforementioned Notice of Exercise.
Yours truly,
Generex Biotechnology Corporation
/s/ Mark A. Fletcher
Mark A. Fletcher
Executive Vice-President, General Counsel
maf:hs
